<SEC-DOCUMENT>0001157523-16-007456.txt : 20161123
<SEC-HEADER>0001157523-16-007456.hdr.sgml : 20161123
<ACCEPTANCE-DATETIME>20161123171051
ACCESSION NUMBER:		0001157523-16-007456
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20161119
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20161123
DATE AS OF CHANGE:		20161123

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			USANA HEALTH SCIENCES INC
		CENTRAL INDEX KEY:			0000896264
		STANDARD INDUSTRIAL CLASSIFICATION:	MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
		IRS NUMBER:				870500306
		STATE OF INCORPORATION:			UT
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35024
		FILM NUMBER:		162017265

	BUSINESS ADDRESS:	
		STREET 1:		3838 WEST PARKWAY BLVD.
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84120-6336
		BUSINESS PHONE:		8019547100

	MAIL ADDRESS:	
		STREET 1:		3838 WEST PARKWAY BLVD.
		STREET 2:		3838 WEST PARKWAY BLVD.
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84120-6336

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	USANA INC
		DATE OF NAME CHANGE:	19930125
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a51465397.htm
<DESCRIPTION>USANA HEALTH SCIENCES, INC. 8-K
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2016 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-size: 10pt; font-family: Times New Roman">
    <p style="text-align: center">
      <br>
      <font style="font-size: 14pt; font-family: Times New Roman"><b>UNITED
      STATES</b></font><br><br><font style="font-size: 14pt; font-family: Times New Roman"><b>SECURITIES
      AND EXCHANGE COMMISSION</b></font><br><br><font style="font-size: 12pt; font-family: Times New Roman"><b>WASHINGTON,
      D.C. 20549</b></font><br><font style="font-size: 12pt; font-family: Times New Roman">______________</font><br>
    </p>
    <p style="text-align: center">
      <font style="font-size: 14pt; font-family: Times New Roman"><b>FORM 8-K</b></font><br><font style="font-size: 12pt; font-family: Times New Roman">______________</font><br>
    </p>
    <p style="text-align: center">
      <font style="font-size: 12pt; font-family: Times New Roman"><b>CURRENT
      REPORT</b></font><br><br><font style="font-size: 10pt; font-family: Times New Roman">Pursuant
      to Section 13 or 15(d) of</font><br><br>t<font style="font-size: 10pt; font-family: Times New Roman">he
      Securities Exchange Act of 1934</font><br><br><font style="font-size: 10pt; font-family: Times New Roman">Date
      of Report (Date of Earliest Event Reported):</font><br><font style="font-size: 10pt; font-family: Times New Roman">November
      19, 2016</font><br><br><font style="font-size: 24pt"><b>USANA HEALTH
      SCIENCES, INC.</b></font><br><font style="font-size: 10pt; font-family: Times New Roman">(Exact
      name of registrant as specified in its charter)</font><br><br>Utah<br>(State
      or other jurisdiction of incorporation)<br><br>
    </p>
    <div style="text-align:center">
    <table style="margin-bottom: 10.0px; font-size: 10pt; width: 100%; font-family: Times New Roman; margin-left:auto;margin-right:auto" cellspacing="0">
      <tr>
        <td style="white-space: nowrap; padding-left: 0.0px; width: 40%; text-align: center; padding-right: 0.0px" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            0-21116
          </p>
        </td>
        <td style="padding-left: 0.0px; width: 20%; text-align: left" valign="top">
          &#160;
        </td>
        <td style="white-space: nowrap; padding-left: 0.0px; width: 40%; text-align: center; padding-right: 0.0px" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            87-0500306
          </p>
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; width: 40%; text-align: center" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            (Commission File No.)
          </p>
        </td>
        <td style="width: 20%">

        </td>
        <td style="padding-left: 0.0px; width: 40%; text-align: center" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            (IRS Employer Identification
          </p>
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; width: 40%; text-align: center" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td style="width: 20%">

        </td>
        <td style="padding-left: 0.0px; width: 40%; text-align: center" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Number)
          </p>
        </td>
      </tr>
    </table>
    </div>
    <div style="text-align:center">
    <table style="margin-bottom: 10.0px; font-size: 10pt; width: 100%; font-family: Times New Roman; margin-left:auto;margin-right:auto" cellspacing="0">
      <tr>
        <td style="padding-left: 0.0px; text-align: center" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            3838 West Parkway Boulevard<br>Salt Lake City, Utah 84120
          </p>
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; text-align: center" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <font style="font-size: 10pt; font-family: Times New Roman">(Address
            of principal executive offices,</font> <font style="font-size: 10pt; font-family: Times New Roman">Zip
            Code)</font>
          </p>
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; text-align: center" valign="top">
          <p style="font-size: 10pt; font-family: Times New Roman">
            <font style="font-size: 10pt; font-family: Times New Roman">Registrant&#8217;s
            telephone number, including area code: </font><font style="font-size: 10pt">(801)
            954-7100</font>
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p style="text-align: center">
      <br>

    </p>
    <p>
      <font style="font-size: 10pt; font-family: Times New Roman">Check the
      appropriate box below if the Form 8-K filing is intended to
      simultaneously satisfy the filing obligation of the registrant under any
      of the following provisions:</font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
      <font style="font-size: 10pt; font-family: Times New Roman">Written
      communications pursuant to Rule 425 under the Securities Act (17 CFR
      230.425)</font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
      <font style="font-size: 10pt; font-family: Times New Roman">Soliciting
      material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)</font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
      <font style="font-size: 10pt; font-family: Times New Roman">Pre-commencement
      communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
      240.14d-2(b))</font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
      <font style="font-size: 10pt; font-family: Times New Roman">Pre-commencement
      communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
      240.13e-4(c))</font>
    </p>
    <div style="margin-bottom: 10pt; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; width: 100%">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      <br>
      <b>Item&#160;5.02 &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Departure of Directors or Certain Officers;
      Election of Directors; Appointment of Certain Officers; Compensatory
      Arrangements of Certain Officers.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b>
    </p>
    <p>
      (b),(c),(e)
    </p>
    <p style="text-indent: 30.0px">
      On November 23, 2016, USANA Health Sciences, Inc. (the &#8220;Company&#8221; or
      &#8220;USANA&#8221;) announced a CEO transition plan wherein (i) David A. Wentz has
      made the personal decision to step down as Co-Chief Executive Officer
      and a member of the Board of Directors effective immediately, and (ii)
      Kevin Guest has been appointed as Chief Executive Officer of the
      Company.&#160;&#160;The Company will no longer utilize a Co-CEO management
      structure. The USANA Board of Directors now consists of six directors,
      four of whom are independent.
    </p>
    <p>
      Mr. Guest, age 54, has served as Co-Chief Executive Officer of USANA
      since August 4, 2015 and, prior to that appointment, served as President
      of USANA since August 2014.&#160;&#160;From October 2012 to October 2014, Mr.
      Guest served as President of the Americas, Europe and South Pacific,
      and, prior to that, as President of North America from May 2011 to
      October 2012.&#160;&#160;From July 2008 to May 2011, he was Chief Marketing
      Officer of the Company.&#160;&#160;Mr. Guest first joined USANA on a part-time
      basis in April 2003, as Executive Director of Media and Events.
      Following the Company&#8217;s acquisition of FMG Productions, a media, video,
      and event productions company that was founded by Mr. Guest, he became a
      full-time employee of the Company and was promoted to Vice President of
      Media and Events in February 2004. In January 2006, he was appointed as
      the Company&#8217;s Executive Vice President of Marketing and served in that
      role until July 2008, when he was appointed Chief Marketing Officer.&#160;&#160;
    </p>
    <p style="text-indent: 30.0px">
      As Chief Executive Officer, Mr. Guest will continue to receive an annual
      salary of $636,000, which will be reviewed going forward by the
      Compensation Committee.&#160;&#160;Mr. Guest will also continue to be eligible to
      participate in the Company&#8217;s Executive Bonus Plan, and be eligible to
      receive equity grants under the Company&#8217;s 2015 Equity Incentive Award
      Plan.&#160;&#160;He will also be eligible to participate in the Company&#8217;s 401K
      plan and to receive medical and other benefits coverage, both of which
      are generally available to the Company&#8217;s other employees. There is no
      arrangement or understanding between Mr. Guest and any other persons
      pursuant to which Mr. Guest was selected as Chief Executive Officer.
      There are no family relationships between Mr. Guest and any director or
      executive officer of the Company and there are no relationships between
      Mr. Guest and the Company or any of its subsidiaries that would require
      disclosure pursuant to Item 404(a) of Regulation S-K of the Securities
      Exchange Act of 1934, as amended.
    </p>
    <p style="text-indent: 30.0px">
      In connection with Mr. Wentz&#8217;s resignation, the Company will pay to him
      all earned compensation and any other amounts due and owing to him.&#160;&#160;Mr.
      Wentz&#8217;s participation in the Company&#8217;s 2016 Executive Bonus Plan will be
      determined by the Compensation Committee in early 2017 following 2016
      year-end operating results.&#160;&#160;
    </p>
    <p style="text-indent: 30.0px">
      The Company issued a press release on November 23, 2016 announcing these
      events. A copy of the press release is furnished as Exhibit 99.1 hereto
      and is incorporated herein by reference.&#160;&#160;
    </p>
    <p>
      <b>Item&#160;9.01 &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</b>
    </p>
    <p style="margin-left: 90.0px">
      (d)&#160;&#160;Exhibits
    </p>
    <p>
      99.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Press release issued by USANA Health Sciences,
      Inc. dated November 23, 2016 (furnished herewith).
    </p>
    <div style="margin-bottom: 10pt; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; width: 100%">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="font-size: 10pt; font-family: Times New Roman; text-align: center">
          2
        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: center">
      <br>
      <font style="font-size: 10pt; font-family: Times New Roman"><b>SIGNATURES</b></font><br>
    </p>
    <p style="text-align: justify">
      Pursuant to the requirements of the Securities Exchange Act of 1934, the
      registrant has duly caused this report to be signed on its behalf by the
      undersigned hereunto duly authorized.
    </p>
    <p style="text-align: left">

    </p>
<div style="text-align:left">
    <table style="margin-bottom: 10.0px; font-size: 10pt; width: 100%; font-family: Times New Roman" cellspacing="0">
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 55%">

        </td>
        <td style="padding-left: 0.0px; width: 40%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>USANA HEALTH SCIENCES, INC.</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 55%">

        </td>
        <td style="padding-left: 0.0px; width: 40%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 55%">

        </td>
        <td style="padding-left: 0.0px; width: 40%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; width: 5%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td style="padding-left: 0.0px; width: 55%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td style="padding-left: 0.0px; width: 40%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>By: </b>/s/ Paul A. Jones
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 55%">

        </td>
        <td style="padding-left: 0.0px; width: 40%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Paul A. Jones, Chief Financial Officer
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 55%">

        </td>
        <td style="padding-left: 0.0px; width: 40%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; width: 5%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Date:
          </p>
        </td>
        <td style="padding-left: 0.0px; width: 55%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            November 23, 2016
          </p>
        </td>
        <td style="width: 40%">

        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <p style="text-align: center">
      3
    </p>
  </body>
</html>
<!--<!DOCTYPE html
     PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN"
     "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">-->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a51465397ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2016 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-size: 8pt; font-family: Times New Roman">
    <p style="text-align: right">
      <b>Exhibit 99.1</b>
    </p>
    <p style="text-align: center">
      <font style="font-size: 12pt; font-family: Times New Roman"><b>USANA
      Health Sciences Announces CEO Transition Plan and Appoints Kevin Guest
      Chief Executive Officer</b></font>
    </p>
    <p>
      SALT LAKE CITY--(BUSINESS WIRE)--November 23, 2016--USANA Health
      Sciences, Inc. (NYSE: USNA) today announced a CEO transition plan. Dave
      Wentz has made the personal decision to step down as Co-CEO and a member
      of the Board of Directors of the Company. The Board of Directors has
      appointed current Co-CEO, Kevin Guest, as CEO of the Company. The
      Company will no longer utilize a Co-CEO management structure. The USANA
      Board of Directors now consists of six directors, four of whom are
      independent.
    </p>
    <p>
      Commenting on his transition, Mr. Wentz said, &#8220;I am grateful for my long
      tenure with USANA and am proud of what we have accomplished over the
      past 24 years. USANA has always been, and will remain, a positive
      influence for so many lives, including my own, and I am confident in the
      Company&#8217;s future under Kevin&#8217;s leadership. I am looking forward to
      spending more time with my family and continuing to advocate for the
      direct sales industry as Chairman of the Direct Selling Education
      Foundation.&#8221;
    </p>
    <p>
      Gilbert Fuller, Chairman of the Governance, Risk and Nominating
      Committee of the Board of Directors, said, &#8220;Dave has made an incredible
      contribution to our organization over the past two decades. He has
      skillfully led the Company to multiple years of record sales and
      customer growth and helped the Company navigate both anticipated and
      unanticipated challenges. We are grateful for his dedication and hard
      work in the many roles he has held with USANA and wish him all the best
      going forward.&#8221;
    </p>
    <div style="margin-bottom: 10pt; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; width: 100%">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      Commenting on the appointment of Mr. Guest as CEO, Dr. Myron Wentz,
      Chairman of the Board, noted, &#8220;We are pleased to name Kevin Guest as CEO
      of USANA. Kevin has led USANA in a variety of roles for more than 20
      years, including President and most recently as Co-CEO. In each role,
      Kevin has demonstrated sound leadership, integrity and judgment. Perhaps
      most importantly, Kevin has earned the trust, respect and admiration of
      countless USANA Associates, customers and employees around the world as
      he has served them. On behalf of the Board, we are grateful to Kevin for
      his great commitment and leadership to USANA in its mission to improve
      the health and nutrition of individuals and families around the world.&#8221;
    </p>
    <p>
      Kevin Guest commented, &#8220;I am honored by the trust and confidence the
      Board of Directors has placed in me to lead USANA going forward. Dave
      and I have worked side by side to achieve many goals over the years, and
      I have the utmost respect for him. I also have complete confidence in,
      and respect for, the leadership team we have in place at USANA. Our team
      has talent and experience in each of the key leadership positions and is
      committed to USANA&#8217;s mission. As demonstrated by the Board&#8217;s recent
      decision to split the stock, we are confident that the strategies we
      have in place will help USANA achieve its long-term growth potential.&#8221;
    </p>
    <p>
      <b>About USANA</b>
    </p>
    <p>
      USANA develops and manufactures high-quality nutritional supplements,
      healthy foods and personal care products that are sold directly to
      Associates and Preferred Customers throughout the United States, Canada,
      Australia, New Zealand, Hong Kong, China, Japan, Taiwan, South Korea,
      Singapore, Mexico, Malaysia, the Philippines, the Netherlands, the
      United Kingdom, Thailand, France, Belgium, Colombia and Indonesia. More
      information on USANA can be found at <u>http://www.usanahealthsciences.com</u>.
    </p>
    <div style="margin-bottom: 10pt; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; width: 100%">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      <b>Safe Harbor</b>
    </p>
    <p>
      This press release contains forward-looking statements within the
      meaning of Section 27A of the Securities Act and Section 21E of the
      Securities Exchange Act. Our actual results could differ materially from
      those projected in these forward-looking statements, which involve a
      number of risks and uncertainties, including global economic conditions
      generally, reliance upon our network of independent Associates, the
      governmental regulation of our products, manufacturing and marketing
      risks, adverse publicity risks, and risks associated with our
      international expansion. The contents of this release should be
      considered in conjunction with the risk factors, warnings, and
      cautionary statements that are contained in our most recent filings with
      the Securities and Exchange Commission.
    </p>
    <p>
      CONTACT:<br>USANA Health Sciences, Inc.<br>Investors contact:<br>Joshua
      Foukas, 801-954-7823<br>Investor Relations<br><u>investor.relations@us.usana.com</u><br>or<br>Media
      contact:<br>Dan Macuga, 801-954-7280<br>Public Relations
    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
